The eTRANSAFE project1 is a strategically important project that has been developing a translational technology infrastructure to support drug safety assessments. The project started around 5 years ago and has been jointly funded by the European Innovative Medicines Initiative alongside the pharmaceutical industry. The partners on the project include representatives from the pharmaceutical industry, academia, and technology companies.

The project focused on the sharing and integration of thousands of proprietary pre-clinical studies leveraging the SEND (Standard for the Exchange of Nonclinical Data) format. This allows the review of study data from different pharmaceutical companies, harmonizing the toxicity studies. The studies have been integrated into a technology platform coupled with additional solutions, including search and data visualization capabilities, predictive modelling, tools to support the handling of treatment-related findings, databases with clinical findings, and translational ontologies, to name a few.

The policies, strategies and technologies developed as part of this project will have a significant impact in enhancing the speed and quality of drug safety assessments as well as supporting the 3Rs and streamlining program planning activities in the preclinical and clinical space.

The final open meeting2 of the current consortium is scheduled for 22-24 February 2023 and will include speakers from regulatory authorities, industry, and academia. It will highlight the progress to date and will provide a roadmap to the future of translational research.

Representatives from Instem will be attending this meeting and happy to discuss collaborative opportunities. However, if you are unable to attend and would like to discuss, please contact Brenda Finney (


  2. Latest advances in drug safety – eTRANSAFE Final Meeting (

Published by Glenn Myatt

Glenn J. Myatt is the co-founder of Leadscope and currently Senior Vice President, In Silico & Translational Science Solutions at Instem with over 30 years’ experience in computational chemistry/toxicology. He holds a Bachelor of Science degree in Computing, a Master of Science degree in Artificial Intelligence and a Ph.D. in Chemoinformatics. He has published 37 papers, 11 book chapters and three books.